Article

MGMT promoter methylation status in anaplastic meningiomas.

Institute of Neuropathology, University Hospital Münster, Domagkstrasse 19, 48149, Münster, Germany.
Journal of Neuro-Oncology (impact factor: 3.21). 05/2010; 100(3):489-90. DOI:10.1007/s11060-010-0202-0
Source: PubMed
0 0
 · 
0 Bookmarks
 · 
60 Views
  • Source
    Article: Molecular diagnostics of gliomas: state of the art.
    Markus J Riemenschneider, Judith W M Jeuken, Pieter Wesseling, Guido Reifenberger
    [show abstract] [hide abstract]
    ABSTRACT: Modern neuropathology serves a key function in the multidisciplinary management of brain tumor patients. Owing to the recent advancements in molecular neurooncology, the neuropathological assessment of brain tumors is no longer restricted to provide information on a tumor's histological type and malignancy grade, but may be complemented by a growing number of molecular tests for clinically relevant tissue-based biomarkers. This article provides an overview and critical appraisal of the types of genetic and epigenetic aberrations that have gained significance in the molecular diagnostics of gliomas, namely deletions of chromosome arms 1p and 19q, promoter hypermethylation of the O6-methylguanine-methyl-transferase (MGMT) gene, and the mutation status of the IDH1 and IDH2 genes. In addition, the frequent oncogenic aberration of BRAF in pilocytic astrocytomas may serve as a novel diagnostic marker and therapeutic target. Finally, this review will summarize recent mechanistic insights into the molecular alterations underlying treatment resistance in malignant gliomas and outline the potential of genome-wide profiling approaches for increasing our repertoire of clinically useful glioma markers.
    Acta Neuropathologica 11/2010; 120(5):567-84. · 9.32 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.